Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The role of bevacizumab in ovarian cancer--an evolving story.

× No keyword cloud information.

12 in total

1. Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment.

Authors: Melissa K Brunckhorst; Yin Xu; Rong Lu; Qin Yu
Journal: Am J Pathol Date: 2014-08 Impact factor: 4.307

2. F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo.

Authors: Ira Winer; Shouyan Wang; Yong-Eun Koo Lee; Youg-Eun Koo Lee; Wenzhe Fan; Yusong Gong; Daniela Burgos-Ojeda; Greg Spahlinger; R Kopelman; Ronald J Buckanovich
Journal: Cancer Res Date: 2010-10-19 Impact factor: 12.701

3. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.

Authors: Hanna Sallinen; Maarit Anttila; Johanna Narvainen; Jonna Koponen; Kirsi Hamalainen; Ivana Kholova; Tommi Heikura; Pyry Toivanen; Veli-Matti Kosma; Seppo Heinonen; Kari Alitalo; Seppo Yla-Herttuala
Journal: Mol Ther Date: 2008-12-02 Impact factor: 11.454

Review 4. Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review.

Authors: Susan E Pories; Gerburg M Wulf
Journal: Breast Cancer (Dove Med Press) Date: 2010-06-21

5. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.

Authors: Halla S Nimeiri; Amit M Oza; Robert J Morgan; Gregory Friberg; Kristen Kasza; Leonardo Faoro; Ravi Salgia; Walter M Stadler; Everett E Vokes; Gini F Fleming
Journal: Gynecol Oncol Date: 2008-04-18 Impact factor: 5.482

6. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.

Authors: Joshua P Kesterson; Paulette Mhawech-Fauceglia; Shashikant Lele
Journal: Gynecol Oncol Date: 2008-08-16 Impact factor: 5.482

Review 7. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.

Authors: Nikos G Gavalas; Alexandra Karadimou; Meletios A Dimopoulos; Aristotelis Bamias
Journal: Clin Dev Immunol Date: 2011-01-24

8. Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study.

Authors: Girolamo Ranieri; Cristina Ferrari; Alessandra Di Palo; Ilaria Marech; Mariangela Porcelli; Gianmarco Falagario; Fabiana Ritrovato; Luigi Ramunni; Margherita Fanelli; Giuseppe Rubini; Cosmo Damiano Gadaleta
Journal: Int J Mol Sci Date: 2017-07-06 Impact factor: 5.923

Review 9. Advances in ovarian cancer therapy.

Authors: Alexander J Cortez; Patrycja Tudrej; Katarzyna A Kujawa; Katarzyna M Lisowska
Journal: Cancer Chemother Pharmacol Date: 2017-12-16 Impact factor: 3.333

Review 10. Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.

Authors: Robert Cornelison; Danielle C Llaneza; Charles N Landen
Journal: Int J Mol Sci Date: 2017-10-18 Impact factor: 5.923